Wellington Management Group LLP Allovir, Inc. Transaction History

Wellington Management Group LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$2.15 - $3.64 $430,382 - $728,647	200,178 Added 50.39%	597,434 $1.28 Million
Q2 2023 Aug 14, 2023	BUY	$3.17 - $5.82 $1.26 Million - $2.31 Million	397,256 New	397,256 $1.35 Million
Q4 2021 Feb 11, 2022	SELL	$12.94 - $25.99 $3.47 Million - $6.97 Million	-267,996 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$16.97 - $25.06 $4.55 Million - $6.72 Million	267,996 New	267,996 $6.72 Million

43.3M

14.9K

200

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $906M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.